Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
NCT01267188
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Tardive Dyskinesia
Interventions
DRUG:
NBI-98854
Sponsor
Neurocrine Biosciences